accountProactive Investors Australia LCT and Otsuka to co-develop treatment for Parkinson's disease Voxy Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the signing of an agreement with Otsuka Pharmaceutical Factory, Inc. (Otsuka) to co-develop NTCELL for the treatment of Parkinson's disease and other neurological disorders. Living Cell Technologies partners with Japanese...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to LCT and Otsuka to co-develop treatment for Parkinson's disease - Voxy
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account